Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699631 · ClinicalTrials.gov registry record · Phase 2
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
A Phase 2 study of Hematologic Malignancy, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT03699631 is a Phase 2 study of Hematologic Malignancy that has completed, run by Medical College of Wisconsin. The registered enrollment target is 29 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03699631, a Phase 2 study of Hematologic Malignancy, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II open-label trial designed to evaluate the efficacy of tocilizumab in improving GVHD-free/relapse-free survival (GRFS) after allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.
Conditions Studied
Interventions
- DRUG Tacrolimus
- DRUG Tocilizumab
- DRUG Methotrexate
Study Locations (1)
Wisconsin
- Froedtert Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-11-06 |
| Est. Completion | 2023-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03699631
The ClinicalTrials.gov registry entry for NCT03699631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (87% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 3 interventions - of which Tacrolimus is the first listed.
NCT03699631 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03699631 about?
NCT03699631 is a clinical study titled "PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant". This is a phase II open-label trial designed to evaluate the efficacy of tocilizumab in improving GVHD-free/relapse-free survival (GRFS) after allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.
What is the current status of trial NCT03699631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2018-11-06. Estimated completion is 2023-04-01.
What conditions does trial NCT03699631 study?
This clinical trial studies the following conditions: Hematologic Malignancy.
What interventions are being tested in trial NCT03699631?
The interventions under investigation include: Tacrolimus (DRUG), Tocilizumab (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT03699631?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03699631 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
-
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.